Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

  • STATUS
    Recruiting
  • End date
    Nov 1, 2022
  • participants needed
    46
  • sponsor
    Sabine Mueller, MD, PhD
Updated on 20 December 2021
platelet count
renal function
absolute neutrophil count
monoclonal antibodies
nitrosoureas
glomerular filtration rate
primary tumor
myelosuppressive chemotherapy
biologics
atypical teratoid/rhabdoid tumor
craniospinal irradiation

Summary

This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC).

This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).

Description

This is an open label, multi-center, Phase I study to assess the safety of administering MV-NIS directly into the tumor bed (for locally recurrent medulloblastoma or ATRT patients) or into the subarachnoid space (for disseminated recurrent medulloblastoma or ATRT patients).

For locally recurrent patients (patients in the first arm) MV-NIS will be directly administered into the tumor bed following a standard of care surgical resection. For patients with disseminated recurrence (patients in the second or third arm), MV-NIS will be injected via lumbar puncture (LP).

Patients in the second arm will receive a one-time administration of MV-NIS. Patients will be closely monitored for 30 days after injection, and then followed for evaluation of 6 month progressive free survival and overall response rate.

Patients in the third arm will receive two administrations of MV-NIS. Patients will be closely monitored for 56 days after injection, and then followed for evaluation of 4 month progressive free survival.

Details
Condition Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
Treatment Modified Measles Virus, Modified Measles Virus Lumbar Puncture
Clinical Study IdentifierNCT02962167
SponsorSabine Mueller, MD, PhD
Last Modified on20 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

• For stratum A, patients must have local recurrent disease (defined as negative spine MRI
and negative cytology within 21 days prior to study registration) and undergo resection of
local recurrence as part of their standard of care. Children must have undergone what is
considered the standard of care as upfront therapy including either surgery followed by
high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery
radiation and chemotherapy
For stratum B, patients must have disseminated recurrent disease (defined as
multifocal disease, positive spine MRI including leptomeningeal disease and/or
positive cytology within 21 days prior to study registration) and have adequate
Prior Therapy
cerebrospinal fluid (CSF) flow based on spine MRI with no evidence of bulky disease or
if bulky disease is present based on a CSF flow study per institutional guidelines
Children must have undergone what is considered the standard of care as upfront
therapy including either surgery followed by high dose chemotherapy with stem cell
rescue or multi-modality therapy of surgery, radiation and chemotherapy
For stratum C, patients must have disseminated recurrent disease (defined as
multifocal disease, positive spine MRI including leptomeningeal disease and/or
Bone Marrow Transplant: Patient must be
positive cytology within 21 days prior to study registration) and have adequate
cerebrospinal fluid (CSF) flow based on spine MRI with no evidence of bulky disease or
if bulky disease is present based on a CSF flow study per institutional guidelines
Radiation
Children must have undergone what is considered the standard of care as upfront
Patients must have
therapy including either surgery followed by high dose chemotherapy with stem cell
rescue or multi-modality therapy of surgery, radiation and chemotherapy
The patient must have failed at least one prior therapy - surgery followed by high
dose chemotherapy with stem cell rescue or multi-modality therapy of surgery
radiation and chemotherapy - prior to study registration. Patients must have fully
recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or
radiotherapy prior to entering this study
o Myelosuppressive chemotherapy: Patients must have received their last dose of known
myelosuppressive anticancer chemotherapy at least three weeks prior to study
registration or at least six weeks prior if nitrosourea
o Biologic agent: Patient must have recovered from any acute toxicity potentially
Adequate Bone Marrow Function Defined as
related to the agent and received their last dose of the biologic agent ≥ 7 days prior
to study registration
For agents that have known adverse events occurring beyond 7 days after
Adequate Renal Function Defined as
administration, this period must be extended to beyond the time during which adverse
events are known to occur. The duration of this interval should be discussed with the
A serum creatinine based on age/gender as follows
study chair
Maximum Serum/Creatinine (mg/dL)
For biologic agents that have a prolonged half-life, the appropriate interval since
Age Male Female
last treatment should be discussed with the Study Chair prior to registration
Monoclonal antibody treatment: At least three half-lives must have elapsed prior
to <6 years 0.8 0.8
to registration. Such patients should be discussed with the study chair prior to
to <10 years 1 1
registration. For bevacizumab, patients must have received last dose ≥ 32 days
to <13 years1.2 1.2
prior to study registration
to <16 years1.5 1.4
≥ 6 months since allogeneic bone marrow transplant prior to registration
Adequate Liver Function Defined as
≥ 3 months since autologous bone marrow/stem cell prior to registration
Serum albumin less than or equal to 2 g/dL
Had their last fraction of local irradiation to primary tumor ≥2 weeks prior to
registration for local palliative radiation therapy (XRT) (small port)
Had their last fraction of craniospinal irradiation ≥ 12 weeks prior to registration
• Age ≥ 12 months to less than or equal to 39 years of age
• Karnofsky ≥ 50 for patients ≥ 16 years of age, and Lansky ≥ 50 for patients < 16
years of age (See Appendix A). Patients who are unable to walk because of paralysis
but who are up in a wheelchair, will be considered ambulatory for the purpose of
assessing the performance score. Patients with pre-existing neurological deficits need
to be stable prior to surgery or LP as determined by the investigator
document
• Cluster of Differentiation 4 (CD4) (>= 200/microliter)
• Organ Function Requirements (within 7 days prior to study registration)
Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3 and
Platelet count ≥ 100,000/mm3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment)
Creatinine clearance or radioisotope glomerular filtration rate (GFR) greater
than or equal to 70 milliliters (mL)/min/1.73 m2 or
- 2 years 0.6 0.6
years 1.7 1.4 The threshold creatinine values in this table were derived from the
Schwartz formula for estimating GFR utilizing child length and stature data published
by the Centers for Disease Control and Prevention (CDC)
Bilirubin (sum of conjugated + unconjugated) less than or equal to 1.5 x upper
limit of normal (ULN) for age and
serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) less
than or equal to 110 U/L and
• The effects of MV-NIS on the developing human fetus are unknown. For this
reason, females of child-bearing potential and males must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to
study entry, for the duration of study participation and 4 months after
completion of MV-NIS administration. Should a female become pregnant or suspect
she is pregnant while she or her partner is participating in this study, she
should inform her treating physician immediately
• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

Patients who are receiving any other investigational agents
Patients with known HIV positivity
Exposure to household contact with known immunodeficiency
History of chronic hepatitis B or C infection
History of organ transplantation
Patients with evidence of extraneural disease
Patients who have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or
mitomycin C) or radiotherapy within 2 weeks prior to entering the study for local
palliative XRT (small port) and within 12 weeks prior for patients that received
craniospinal XRT
Patients who have not recovered from acute adverse events due to agents
administered more than 4 weeks earlier
History of allergic reactions attributed to compounds of similar chemical or
biologic composition to measles virus vaccination
Uncontrolled intercurrent illness including, but not limited to, ongoing or
active infection, symptomatic congestive heart failure, unstable angina pectoris
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements
Female patients of childbearing potential must not be pregnant or
breast-feeding
Female patients of childbearing potential must have a negative serum or urine
pregnancy test (within 7 days prior to study registration)
Patients with inability to return for follow-up visits or obtain follow-up
studies required to assess toxicity to therapy
Patients on chronic steroids or other immunosuppressive agents. Note
Patients that are currently using inhaled, intranasal, ocular, topical or
other non-oral or non-IV steroids may be eligible
Inability to undergo magnetic resonance (MR) imaging to assess disease
status
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note